Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Sandoz announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorization for…
Read More...
Read More...